Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
X-TRAP: Capecitabine + Aflibercept in Metastatic Colorectal Cancer
NCT01661972Phase 2Completed
- Sponsor
- John Strickler
- Start
- Aug 2012
- Primary completion
- Jun 2016
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of aflibercept in metastatic colorectal cancer (mCRC) (2 arms), sponsored by John Strickler. Primary endpoints: Recommended Phase II Dose up to 1 year, Dose-Limiting Toxicities at 28 days and 1 more. Started Aug 2012; status: completed.
02
Drugs
aflibercept
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01661972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01661972.